A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Clinical trial NCT00179738 · TERMINATED
Trial details
- NCT number
- NCT00179738
- Sponsor
- Celgene Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-04-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.